#United States #Boulder #Edgewise Therapeutics #Muscle Disease #EWTX

Edgewise Therapeutics Grants Inducement Stock Options

Boulder, Colorado – On January 5, 2026, Edgewise Therapeutics, Inc. (Nasdaq: EWTX) declared it has awarded inducement stock options to a total of 119,250 shares of common stock to four newly hired non-executive employees. This move aligns with its 2024 Inducement Equity Incentive Plan, aimed at supporting the company's expansion in the muscle disease biopharmaceutical landscape.

These inducement stock options, which were granted on December 31, 2025, are part of Edgewise’s efforts to attract and retain top talent in a highly competitive industry. The exercise price for each option is set at $24.82, corresponding to the closing stock price on the grant date. Vesting is structured with an initial 25% of the shares becoming available one year after each employee's start date, followed by a monthly vesting schedule of one forty-eighth (1/48th) of the shares thereafter, contingent on continued employment.

The company’s commitment to incentivizing new hires through these inducements is guided by Nasdaq Listing Rule 5635(c)(4), which aims to facilitate the onboarding of skilled professionals essential for driving impactful research and development.

About Edgewise Therapeutics

Edgewise Therapeutics has positioned itself at the forefront of developing therapeutics for muscular dystrophies and severe cardiac conditions. The company's extensive expertise in muscle physiology enables it to innovate groundbreaking treatments that have the potential to transform patient care.

Some of its leading candidates include Sevasemten, an oral fast skeletal myosin inhibitor currently in late-stage clinical trials targeting Becker and Duchenne muscular dystrophies. Additionally, EDG-7500 serves as a novel cardiac sarcomere modulator designed for treating hypertrophic cardiomyopathy, and EDG-15400 aims to address heart failure, now progressing through Phase 1 clinical trials.

Edgewise’s dedication is evident; its entire team is committed to changing lives of patients affected by serious muscle diseases. Their innovative approach, alongside the recent stock option grants, reflects a strategic investment in both human capital and the advancement of medical treatments.

In the biopharma sector, where advancements can make a significant difference in patients' lives, attracting talented individuals is crucial. As Edgewise continues to grow its research and development efforts, the inducement grants not only foster talent but also signal to the market its ambition for innovation and leadership in the field of muscle diseases.

For further details on Edgewise Therapeutics and its initiatives, please visit www.edgewisetx.com or engage with the company through its LinkedIn and X platforms.